Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158931 | 0.87 | GPR119 (0.61) | GPR119SLC6A9CHRM4MAPTHDAC1 | |
| SCHEMBL23560705 | 0.87 | GPR119 (0.61) | GPR119SLC6A9CHRM4MAPTHDAC1 | |
| SCHEMBL31713534 | 0.84 | NR1H2 (0.48) | GPR119NR1H2SLC6A9CHRM4MAPT | |
| SCHEMBL5467171 | 0.78 | GPR119 (0.65) | GPR119MAPT | |
| SCHEMBL1448169 | 0.76 | GPR119 (0.65) | GPR119SLC6A7MAPTHDAC1MAP4K4 | |
| SCHEMBL12740835 | 0.76 | GPR119 (0.65) | GPR119SLC6A7MAPTHDAC1MAP4K4 | |
| SCHEMBL23560775 | 0.76 | GPR119 (0.62) | GPR119SLC6A9SLC6A7MAPTHDAC1 | |
| SCHEMBL1448170 | 0.76 | GPR119 (0.65) | GPR119SLC6A7MAPTHDAC1MAP4K4 | |
| SCHEMBL21521413 | 0.75 | GPR119 (0.59) | GPR119SLC6A9CHRM4HDAC1MAP4K4 | |
| SCHEMBL28966548 | 0.75 | GPR119 (0.59) | GPR119SLC6A9CHRM4HDAC1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | GPR119 138/4885NR1H2 1735/4885SLC6A9 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.